ISSN: 2755-9351

Journal of Alzheimer's Disease & Reports

SCIENTIFIC Research and Community

Research Article

Open Access

From APOE4-Dependent Glial Lipid Droplets to Genotype-Sensitive Intervention: Reappraising Palm-Derived Bioactives in Alzheimer's Disease Through a Review

Loso Judijanto

IPOSS Jakarta, Indonesia

ABSTRACT

Alzheimer's disease encompasses disturbances in lipid transport, membrane composition, lysosomal processing, and glial immunometabolism that are incompletely captured by amyloid-centred or generic antioxidant explanations. APOE ε4, a major genetic risk allele for late-onset Alzheimer's disease, provides a mechanistic entry point because APOE4-associated glial lipid droplets may accompany inflammatory dysfunction and neuronal injury. This qualitative literature review critically integrates research published during 2020–2026 on APOE-dependent brain lipid homeostasis with studies of palm-derived tocotrienols, phytosterols, squalene, and fatty-acid fractions. Rather than equating lipid-droplet abundance with toxicity, the review differentiates adaptive lipid sequestration from persistent lipid-storage states linked to defective lipid trafficking, lipophagy, and cellular stress. Evidence is strongest for the pathological relevance of APOE4-sensitive glial lipid handling, more indirect for individual bioactive mechanisms, and presently inadequate for claims of APOE4-stratified cognitive benefit from palm-derived ingredients. Tocotrienols merit focused investigation for lipid-peroxidation and signalling effects; phytosterols require sterol-species and compartment-specific evaluation; squalene evidence remains preliminary; and saturated fatty-acid fractions warrant particular caution. An evidence-calibrated framework specifies genotype-isogenic human glial models, lipidomic and spatial readouts, pharmacokinetic exposure verification, glia–neuron functional endpoints, and staged translational decision rules. The review argues that the therapeutically meaningful target is restoration of lipid-processing competence rather than indiscriminate depletion of intracellular lipid droplets.

***Corresponding author**

Loso Judijanto IPOSS Jakarta, Indonesia.

Received: October 24, 2026; **Accepted:** October 26, 2026; **Published:** October 31, 2026

Keywords

Alzheimer's Disease, APOE4, Lipid Droplets, Microglia, Astrocytes, Tocotrienols, Phytosterols, Squalene, Lipophagy, Palm-Derived Bioactives

JEL Classification: I10; I12; I18; O31; Q56

Introduction

Background: Lipid Metabolism and the Changing Alzheimer's Disease Model

Alzheimer's disease (AD) research has moved beyond a narrow competition between amyloid and tau hypotheses toward an understanding of pathogenic systems in which neuronal proteostasis, vascular health, lipid trafficking, immune responses, and metabolic resilience mutually influence one another. The current biomarker-based disease framework provides a disciplined basis for defining disease stage, yet biomarker positivity alone does not explain why genetically or environmentally distinct individuals experience different rates of cellular dysfunction and clinical decline. Brain lipid biology offers an especially relevant layer because membranes, myelin, synapses, phagolysosomes, and lipid droplets are all constructed or maintained through tightly regulated lipid flux. APOE is not merely an amyloid-binding factor: its isoforms affect how glial cells package, deliver, clear, and remodel lipids during ageing and pathological challenge

The APOE ε4 allele is one of the most consequential common genetic susceptibility factors for late-onset AD, but genotype must not be mistaken for deterministic fate. Population association, cellular causal perturbation, and individual therapeutic prediction are different inferential levels. Genome-wide analyses implicate broader immune, endocytic, and lipid pathways; therefore the APOE4 phenotype probably interacts with genes affecting microglial sensing, phagocytosis, and trafficking. In this context, lipid droplets are attracting attention not simply because they can be visualised in stressed cells, but because their composition, turnover, protein partners, and relationship to lysosomes may alter neuronal survival. A scientifically useful intervention framework must accommodate genetic background, disease stage, and cell type rather than assign uniform meaning to an APOE4 carrier state

Urgency: Distinguishing Dysfunctional Lipid Storage from Protective Sequestration

The demonstration of lipid-droplet-rich, inflammatory microglial states in ageing and APOE4-related experimental settings sharpened an important conceptual problem. Accumulation is observable, but biological significance cannot be inferred from droplet count alone. Neutral lipid storage can buffer excess free

fatty acids and protect membranes from lipotoxicity; a persistent droplet population with altered triglycerides, oxidised lipids, impaired autophagic turnover, and inflammatory responses may instead signal maladaptive processing. Treating every droplet as harmful would ignore the fundamental biology of organelle contact, lipid exchange, and stress adaptation. Conversely, assuming that droplets are always protective would underestimate evidence that distinct disease-associated microglial states can damage neurons.

The problem is clinically urgent because intervention proposals often leap from generic antioxidant activity to claims of neuroprotection without demonstrating brain exposure, APOE-dependent target engagement, or improvement in glia–neuron function. Palm oil is a chemically heterogeneous source of minor constituents and fatty-acid fractions, not one pharmacological entity. Tocotrienols, sterols, squalene, and palmitate differ in molecular structure, uptake, distribution, metabolic handling, and likely cellular effects. Some compounds may constrain damaging lipid oxidation, whereas others could affect sterol gradients or substrate availability in ways that depend on cellular state. A credible review must therefore evaluate each fraction independently and explain what experiments would be needed before translation can be justified

Scope, Questions and Substantive Contribution

This review addresses whether palm-derived molecules offer testable, mechanistically specific opportunities to influence APOE4-associated glial lipid dysfunction, not whether their consumption currently prevents or treats AD. Its questions concern APOE isoform-dependent lipid transport, glial droplet phenotypes, which compound–pathway intersections are credible, how opposing biological effects should be interpreted, and what evidence constitutes translational progress. We integrate AD-specific observations with cellular lipid biology and compound pharmacology while explicitly identifying indirect studies whose models do not reproduce APOE4-associated neuropathology. The proposed contribution is an APOE-stratified evaluation framework that moves from chemical identity and exposure through lipidomic target engagement to brain-cell functional rescue and, only subsequently, clinically meaningful outcomes

Literature Review: Conceptual and Theoretical Foundations

APOE Isoforms as Regulators of Brain Lipid Traffic

APOE is synthesised principally by astrocytes under many physiological conditions and participates in the formation of lipoprotein particles that distribute cholesterol and phospholipids among brain cells. In disease-associated circumstances microglia may also express APOE strongly, linking its biology to immune activation and tissue-remodelling responses. The ε2, ε3, and ε4 isoforms differ in interactions with lipid cargo, receptors, and intracellular compartments; the consequences cannot be compressed into a simple ranking of beneficial versus harmful cholesterol concentrations. What matters may be where a particular sterol accumulates, how efficiently a lipoprotein is lipidated, and whether recipient lysosomes can dispose of its cargo. Theories of AD that incorporate these processes better connect genetics to cellular dysfunction than isolated measures of blood cholesterol.

Human astrocyte experiments indicate that APOE4 can perturb neuron–astrocyte fatty-acid coupling and alter the cholesterol supplied to neuronal membranes, potentially modifying lipid-raft formation and amyloid generation. Another line of work links APOE4-dependent lysosomal cholesterol buildup to disturbed mitochondrial function, underscoring that a molecule can be abundant but biologically unavailable in the compartment requiring it. Meanwhile, dysregulated cholesterol and extracellular matrix-related programmes have been observed across human iPSC-derived astrocytes and microglia. Taken together, these data imply that a successful intervention might have to restore trafficking and utilisation rather than merely lower total cellular sterol content.

Subcellular localisation adds a further dimension to this framework. Windham et al. (2024) demonstrated that APOE can associate with astrocytic lipid droplets through endoplasmic-reticulum–droplet contacts and influence triglyceride saturation and droplet size; APOE4-expressing astrocytes showed distinct properties relevant to lipid turnover and susceptibility to lipid peroxidation. These findings complement lysosomal cholesterol studies because they identify a droplet-associated role of ApoE that cannot be inferred from its extracellular lipoprotein transport alone, although the experiments do not establish that a palm-derived compound corrects the phenotype.

The importance of cellular context also extends beyond astrocytes and microglia. APOE4-related cholesterol dysregulation in oligodendrocytes can impair myelination, showing why a glial therapy should be assessed for broader central nervous system effects. Astrocyte lipid disturbances may arise before pronounced neuronal loss, and glia exchange fatty acids, cholesterol, and metabolic substrates with neurons through several routes. Consequently, interventions that appear beneficial in a monoculture may simply divert lipid burden to another cell type. Co-culture systems, cell-specific lipid tracing, and cell-resolved phenotyping are essential to determine whether apparent rescue represents improvement in system-level lipid homeostasis.

Figure 1 integrates astrocytic lipid packaging, microglial processing and neuronal membrane requirements into an APOE-sensitive model of lipid exchange. The diagram distinguishes intercellular transport from organelle-level stress and identifies cholesterol mislocalisation, altered lipid cargo and impaired lysosomal or mitochondrial function as possible points of vulnerability. Solid arrows represent experimentally supported relationships in the cited literature, whereas the dashed interaction remains conditional on cell state and experimental setting




Figure 1: APOE Genotype–Sensitive Intercellular Lipid Exchange and Subcellular Processing (Integrative Conceptual Model).

Figure 1 maps major cell-specific exchanges alongside APOE4-associated liabilities; its arrows are deliberately not claims that any proposed palm-derived compound reverses those pathways. In astrocytes, APOE lipidation and cholesterol supply can influence neuronal lipid environments, while microglia face phagocytic lipid loading and degradative demand. The framework clarifies why improvements in one cell type must be evaluated for transferred or displaced stress in neighbouring cells, rather than reported as system-level rescue from a single monoculture

Microglia, TREM2 and Immunometabolic State Transitions

Microglia are both immune sentinels and metabolic scavengers, continuously encountering apoptotic membranes, myelin fragments, synaptic material, and potentially toxic lipid species. TREM2-associated signalling contributes to their ability to respond to chronic phagocytic challenge, with downstream effects on cholesterol handling and bioenergetic state. Experimental enhancement of TREM2-related pathways can improve particular microglial metabolic functions in AD models, but a response that is favourable under one disease stage may not generalise to another. Senescence-associated and disease-associated states further complicate interpretations of a single anti-inflammatory readout. The biologically meaningful question is whether microglia retain the ability to engulf material, process it safely, and support surrounding neurons

Direct manipulation of the APOE isoform in microglial contexts strengthens the case for a genotype-sensitive cellular phenotype. Liu et al. (2023) reported that microglial expression of apoE3, compared with apoE4, supported different responses to amyloid-associated pathology and synaptic function in experimental models, including differences in lipid handling. Using edited human iPSC-derived microglia and neuronal systems, Victor et al. (2022) connected APOE4-induced lipid accumulation to reduced surveillance of neuronal network activity; this provides a functional counterpoint to studies that assess droplets or cytokines without measuring neural communication

APOE-containing lipoproteins can affect microglial activation in an isoform-sensitive fashion, with phospholipid cargo contributing to the response. Recent studies of APOE lipidation and triglyceride metabolism suggest that the physical state of lipid carriers may be as consequential as the presence of APOE protein itself. Therefore, a putative bioactive drug that suppresses cytokine transcription without examining phagocytic competence, lysosomal activity, and lipid efflux could create a misleading impression of therapeutic value. Immunometabolic recovery should be evaluated as a set of coordinated capacities, not as a single decline in an inflammatory marker.

Lipid Droplets, Lipophagy and the Adaptive-To-Maladaptive Transition

Lipid droplets are structured organelles with a neutral lipid core, a phospholipid monolayer, and associated proteins that govern synthesis, mobilisation, and organelle contacts. They can sequester fatty acids released during oxidative or phagocytic stress and potentially limit uncontrolled peroxidation of vulnerable membranes. Their abundance is regulated not only by triglyceride synthesis but by lipolysis, lipophagy, endoplasmic-reticulum contacts, mitochondrial demand, and lysosomal function. Generic staining for neutral lipid is therefore a weak proxy for pathological function. Droplet turnover, lipid species, protein composition, and the cellular stress history must also be analysed (Farese and Walther, 2025; Henne and Cohen, 2026; Zhang et al., 2025).

The pathogenic interpretation gained traction from ageing-associated lipid-droplet-accumulating microglia and from human- and experimental-model observations connecting APOE4/4 to lipid-rich, neurotoxic microglial states. Aβ exposure may provoke a DGAT2-linked droplet programme that accompanies microglial dysfunction; however, another study found triglyceride metabolism essential for specific inflammatory responses and microglial phenotypes. These findings must be read together: inhibition of neutral-lipid synthesis may improve one experimental endpoint while obstructing necessary buffering, energy supply, or phagocytic function in another. The proper hypothesis is context-dependent normalisation of handling, not universal suppression of droplet formation.

A contemporary synthesis of lipid-droplet-accumulating microglia further emphasises the heterogeneity of inflammatory, metabolic and phagocytic states relevant to neurodegeneration. Such reviews

can justify experimental priorities and help reconcile apparently competing mechanisms, but their proposed therapeutic routes should not be mistaken for independent demonstrations of drug efficacy. In particular, pharmacological removal of lipid droplets would need to preserve the short-term buffering functions that protect stressed cellular membranes.

Genetic variation beyond APOE may converge upon lipid-droplet pathways. PICALM risk-related work supports abnormal droplets as a broader AD-linked cellular phenotype, and recent APOE-genotype comparisons indicate remodelling of the astrocytic droplet proteome and dynamics. Reports implicating impaired microglial droplet autophagy in APOE4-linked neuronal degeneration warrant attention, but short mechanistic communications should not be weighted as equivalent to convergent intervention trials. Because glial lipid storage is an endpoint shared by numerous perturbations, causality requires showing that correcting a precisely identified defect improves a second, independently measured cellular function.

Membranes, Oxidative Lipid Injury and Ferroptosis

The lipid-raft hypothesis connects membrane composition and microdomain signalling to amyloid processing, receptor function, and cellular vulnerability. It offers a different mechanistic level from lipid-droplet accumulation: droplets contain neutral storage lipids whereas neuronal and glial membranes contain structural phospholipids and cholesterol arranged into domains. Damage may propagate when oxidation, altered cholesterol availability, or inflammatory processes change membrane integrity and signalling. A compound that reduces membrane lipid peroxidation need not shrink lipid droplets, and a compound that changes cholesterol trafficking may affect amyloid-related pathways without having antioxidant potency. Distinguishing these mechanisms is foundational for causal claims.

Ferroptosis is an iron-dependent form of cell death linked to phospholipid peroxidation and the adequacy of cellular antioxidant defences. Mechanistic work on ferroptosis, including human white-matter injury, shows why oxidised lipid species and redox state deserve explicit measurement in glial experiments. Nevertheless, expression of ferroptosis-associated markers alone is not sufficient evidence that a cell died through this route. Robust research should employ orthogonal assays, rescue interventions, and appropriate controls. Lipid droplets might protect by sequestering peroxidation-prone species under some conditions while sustaining a damaging lipid milieu under others; the transition remains an experimentally defined question, not an intrinsic property of the droplet.

Palm-Derived Constituents as Chemically Separate Candidate Classes

Palm-derived tocotrienols are unsaturated members of the vitamin E family whose individual α, γ, and δ forms differ from tocopherols and from one another. Preclinical literature reports anti-inflammatory and neuronal effects, and recent experiments suggest relevant actions on tau-related signalling or ferroptosis-associated pathways. Yet these observations do not demonstrate correction of APOE4-specific glial lipid flux. Formulation and bioavailability matter because ingested dose, blood concentration, brain entry, cell exposure, and lysosomal concentrations are non-interchangeable variables. The first question is therefore whether a specified tocotrienol isomer can reach relevant compartments at a non-toxic concentration, and only then whether it repairs a defined lipid-handling defect.

Phytosterols require a separate framework. They resemble cholesterol structurally, but their effects on intestinal absorption, circulating sterols, blood–brain exchange, and cerebral metabolism are not equivalent. Cerebrospinal fluid associations and studies of plant sterols and cognitive trajectories illustrate biological relevance without establishing therapeutic direction or causation. Some research has reported potential modulation of inflammatory signalling by stigmasterol; other work reports associations involving pro-inflammatory lipid mediators or genotype-modified cognitive trajectories. The decisive questions include which sterol species is present, whether it enters brain compartments, whether concentrations are pharmacologically realistic, and whether APOE genotype changes tissue response.

Squalene is a sterol-pathway precursor and membrane-related lipid whose pharmacology should not be inferred from that of phytosterols or tocotrienols. An in vitro AD-oriented study examining stress-response signalling provides a preliminary mechanistic clue, but evidence connecting squalene to APOE4-stratified lipid-droplet recovery remains sparse. By contrast, fatty-acid fractions are abundant primary ingredients and must be interpreted through their individual metabolic fate. Palmitic acid is physiologically present and metabolically indispensable in appropriate compartments, but excessive exposure in inflammatory cell models and epidemiological associations with cognitive outcomes justify scrutiny rather than blanket nutritional or therapeutic promotion. Palm origin does not guarantee similar risk–benefit profiles across chemical classes.

Translational Interpretation and the Evidence Hierarchy

The evidentiary chain from chemistry to patient outcome comprises compound identification, reproducible formulation, systemic and cerebral pharmacokinetics, cell-specific molecular target engagement, functional rescue, in vivo disease relevance, and carefully designed clinical endpoints. Reviews or mixed-compound experiments are useful for hypothesis formation but cannot substitute for isomer-resolved causal testing. A randomised trial of tocotrienol-rich vitamin E in CADASIL provides a valuable negative translational comparator: it investigated a different cerebral small-vessel disease, and therefore neither proves nor disproves benefit in AD, yet it warns against extrapolating antioxidant plausibility directly to clinical efficacy. An APOE4-centred review should carry this restraint through every proposed compound evaluation.

Method: Qualitative Literature Review

Design and Epistemological Position

This article adopts a qualitative literature review (QLR), not a systematic literature review, meta-analysis, or scoping review presented under a systematic-search label. Its purpose is interpretive integration across disciplines: to identify mechanistic agreements, reconcile apparent contradictions, separate causal from associative evidence, and construct a theoretically grounded research programme. A narrative QLR is appropriate because direct trials of palm-derived compounds in APOE4-specific AD settings are lacking, while relevant observations are dispersed across glial cell biology, human genetics, lipid biochemistry, formulation science, and neuroinflammation. The synthesis applies critical explanatory comparison rather than pooled effect-size estimation; no PRISMA selection diagram or claim of exhaustive retrieval is made.

Literature Identification, Boundaries and Iterative Searches

The review drew on targeted and iterative searches of PubMed-indexed and publisher-hosted journal materials, supplemented

by forward and backward conceptual citation exploration, for work published between January 2020 and 23 October 2026. Search concepts included "APOE4 AND microglia lipid droplets," "astrocyte cholesterol lysosome Alzheimer," "DGAT2 triglyceride microglia," "TREM2 lipid metabolism," "tocotrienol ferroptosis neurodegeneration," "phytosterol Alzheimer," "squalene neuron stress," and "palmitate microglia." Search combinations evolved as mechanistic links and conflicting findings were identified; the exercise was intentionally not restricted to a frozen, prospectively registered query. Primary research in human brain material and genotype-defined human iPSC models was prioritised for disease-specific inference, while carefully identified review articles provided conceptual context.

Eligibility Logic, Source Appraisal and Analytical Coding

Sources were selected for relevance, peer-reviewed journal publication during the defined period, identifiable bibliographic records, and a meaningful contribution to APOE biology, glial lipid handling, a candidate bioactive, or translational method. Evidence from unrelated cancer or liver cell lines, generic antioxidant challenges, unsupported dietary claims, and non-peer-reviewed material was not treated as direct AD efficacy evidence. Studies were narratively coded into six intersecting domains: genetic context; cell type and model; lipid compartment and species; perturbation or compound identity; measured functional consequences; and translational distance. Appraisal emphasised whether a study manipulated causal mediators, included APOE2/3/4 comparisons, verified exposure, assessed multiple endpoints, or risked conflating lipid abundance with lipid-processing competence.

Synthesis Procedure, Reflexivity and Limitations

Thematic synthesis proceeded through repeated comparison of convergent and discrepant findings, testing each proposed bioactive mechanism against an explicit sequence: chemical specification, physically plausible brain exposure, verified target engagement, cell-specific lipid phenotype, neuronal functional effect, and disease-relevant generalisability. We classify links as direct AD/APOE evidence, adjacent mechanistic evidence, or exploratory hypothesis, rather than assigning unvalidated numerical confidence scores. The qualitative approach inevitably depends on author judgement and can miss publications; selective availability of positive laboratory studies, heterogeneity in human iPSC maturation, formulation variation, and publication bias further constrain inference. These limitations make falsifiable experimental predictions more important than broad efficacy conclusions.

Results: Thematic Findings

Theme I — APOE4 Disrupts Lipid Compartmentalisation Rather Than Simply Increasing Fat

The most consistent synthesis is that APOE4 alters the choreography of lipid movement between cells and subcellular compartments. Astrocytes may transfer fatty acids differently, oversupply neuronal membrane cholesterol under specific conditions, and trap sterols in lysosomes while mitochondria remain metabolically compromised. In oligodendrocytes, impaired cholesterol handling can influence myelin maintenance; in microglia, APOE lipidation and lipoprotein cargo can change inflammatory and metabolic programmes. These are not interchangeable abnormalities. A whole-cell assay reporting unchanged total cholesterol might miss decisive redistribution between lysosome, endoplasmic reticulum, plasma membrane, and storage pools. Consequently, candidate compounds must be assessed against compartment-resolved lipid flux rather than a single global lipid endpoint.

Cell-type-resolved lipidomic studies indicate that even within an amyloid-rich brain, altered lipid species cannot automatically be assigned to a single glial population. In mouse amyloidosis models analysed alongside human postmortem material, Xu et al. (2025) identified a microglia-dependent accumulation of arachidonic-acid-containing bis(monoacylglycero)phosphate, whereas increases in several lysophospholipids were comparatively microglia-independent and associated with astrocytic reactivity or oxidative stress. This separation suggests that APOE-stratified interventions need to track chemically resolved lysosomal and membrane lipid markers by cell type, rather than interpret a single bulk brain lipidomic signal as proof of corrected microglial function.

An important second finding is that APOE genotype influences both baseline cellular state and the response to environmental or disease-associated challenge. Isoform-sensitive phospholipid effects on microglia, disease-linked differences in droplet protein composition, and interactions with other AD risk loci support the need for genotype-stratified experiments. Nevertheless, APOE4 is not sufficient to explain every neurodegenerative trajectory. Background genes, ageing, amyloid load, metabolic disease, sex, and microenvironment plausibly modify the observed phenotype, while some human studies identify sex-by-APOE interactions in relationships between sterol metabolism and cognition. Accordingly, an effect detected only in one engineered cell line should be reported as context-dependent rather than a general APOE4 phenotype.

Theme II — Lipid-Droplet Toxicity is Conditional and Linked to Turnover

Across ageing and AD-oriented studies, lipid-droplet-rich microglial populations can display inflammatory or neuronal-injurious phenotypes. APOE4-associated droplet formation provides a concrete link between genetic risk and cell state; Aβ-induced DGAT2 activity and impaired droplet autophagy offer possible mechanistic routes into persistent storage. Yet the ability to synthesise triglycerides may also help a stressed phagocyte process incoming lipid cargo, so blocking DGAT2 or forcing lipolysis might create new toxicity even if droplet count falls. A functional analysis must therefore distinguish droplet biogenesis rate, size distribution, triglyceride species, oxidised cargo, and flux through lysosomes before interpreting a visible decrease as recovery.

The adaptive-to-maladaptive model resolves an apparent disagreement between lipid-storage biology and disease-focused observations. Early neutral-lipid sequestration may shelter fragile membranes; prolonged accumulation may instead accompany failed degradation or chronic activation. A time-course experiment can detect this reversal by contrasting short and sustained challenge, then measuring whether lipid mobilisation restores homeostasis or exposes the cell to uncontrolled fatty-acid oxidation. The resulting predictions differ by cell type: astrocytes may use lipid stores to support neurons, while microglia may accumulate incompletely digested phagocytic cargo. This finding argues against a simplistic "fewer droplets equals less disease" therapeutic narrative and prioritises turnover assays and neuronal co-culture endpoints.

Figure 2 illustrates why lipid-droplet quantity cannot independently discriminate a protective response from a dysfunctional one. It contrasts transient fatty-acid esterification and membrane protection with persistent droplets accompanied by impaired lipophagy, oxidative cargo and inflammatory signalling. The proposed transition is contingent on time, APOE genotype, cell state and lipid composition, and consequently requires

measurement of droplet turnover and neuronal function rather than staining intensity alone.




Figure 2: Conditional Lipid-Droplet States in Glia: Adaptive Sequestration Versus Persistent Dysfunction.

Figure 2 contrasts potentially adaptive early lipid buffering with persistence associated with altered lysosomal processing or inflammatory phenotypes. Its orange pathway is a disease-contextual possibility, not a claim that every lipid droplet inevitably becomes pathogenic. Pairing lipidomics and turnover measurements with phagocytosis, astrocytic support and neuronal readouts enables investigators to test whether a changed droplet population represents functional recovery.

Theme III — Glial Inflammatory Signalling Cannot be Separated from Lipid Work

Glial inflammation is metabolically expensive and intertwined with the machinery for uptake and degradation. A microglial cell that reduces cytokine production may still be pathologically ineffective if cholesterol trafficking, phagosome maturation, energy supply, or debris clearance deteriorates. TREM2 studies make this interdependence evident: cholesterol metabolism under prolonged phagocytic stress, metabolic stimulation following TREM2 activation, and senescent TREM2-positive states do not support a single universally desirable activation level. The relevant balance is efficient clearance without chronic neurotoxic signalling, while preserving glial trophic functions. The evidence thus favours a multidimensional functional endpoint over isolated NF-κB, NLRP3, or cytokine measures.

The link to inflammasome biology nevertheless offers targeted exploratory routes. For instance, stigmasterol has been examined in microglial inflammatory models involving AMPK, NF-κB, and NLRP3; such findings establish that a molecular interaction can be experimentally probed, not that sterol administration corrects APOE4-dependent droplet pathology. Tocotrienol literature similarly supports anti-inflammatory hypotheses without defining whether changes originate in membrane oxidation, transcriptional control, altered lipid storage, or unrelated upstream responses. Future designs should pair mediator assays with uptake, lysosomal competence, and neuron-survival readouts to determine whether an apparently anti-inflammatory compound genuinely improves the integrated system (Jie et al., 2022; Mathew et al., 2023; Ismail et al., 2020).

Theme IV — Tocotrienols Have the Clearest Oxidative-Lipid Rationale, but No Established APOE4 Rescue

Among the candidate classes, tocotrienols possess the most readily articulated intersection with damaging lipid oxidation. Experimental literature describes neuronal signalling and tau-related effects, and newer comparative work suggests ferroptosis-inhibiting capacity under defined experimental conditions. These results align conceptually with membrane lipid-peroxidation injury and ferroptosis research, but the inferential bridge to APOE4-associated microglial triglyceride dynamics is still missing. Lipid-peroxidation suppression could be protective without normalising lysosomal cholesterol egress, and apparent improvement in a generic stress model cannot validate efficacy in APOE4/4 glia. The specific isomer, formulation, target tissue concentration, and timing relative to injury must all be reported before mechanisms can be compared across studies.

Bioavailability emerges as a major constraint rather than a peripheral formulation detail. Nano-delivery systems can alter systemic exposure and tissue distribution, but tissue biodistribution and in vitro activity still do not demonstrate sufficient unbound concentration in human microglial or astrocytic compartments. Human pharmacokinetic syntheses document the complexity of tocotrienol exposure, making administered dose an unreliable stand-in for CNS target engagement. The negative or neutral translational lesson from a tocotrienol-rich formulation tested in CADASIL cautions against assuming that biomolecular plausibility ensures benefit in complex human brain disease. AD-specific inference requires new studies and should not be borrowed from vascular or other neurological diagnoses.

Theme V — Phytosterols, Squalene and Saturated Fractions Have Divergent Risk–Benefit Profiles

The phytosterol evidence is intriguing but internally heterogeneous. Plant sterols measured in cerebrospinal fluid correlate with aspects of pathology and progression; observational and genetic-inference studies associate sterol-related exposures or profiles with cognitive or neurodegenerative outcomes. A sterol may also act through peripheral cholesterol absorption, systemic lipid profiles, or

microbiome-related pathways rather than directly entering a brain cell. Animal dietary studies of plant sterol availability and brain inflammatory mediators raise further questions about direction of effect. Consequently, observational associations should not be converted into recommendations for brain phytosterol loading; molecular identity and compartmental localisation must be evaluated explicitly (Jahn et al., 2021; Guo et al., 2024; Clark et al., 2023; Reinicke et al., 2021).

Squalene requires an even more cautious interpretation. A reported cell-based AD-model association with endoplasmic-reticulum stress signalling represents an investigational starting point but not evidence that squalene normalises ApoE lipidation or glial droplet turnover. Saturated fatty-acid fractions present a different issue: palmitic acid is a normal participant in brain metabolism, yet dysregulated high exposure or altered saturated-fatty-acid profiles may influence microglial activation and correlate with adverse cognitive states in some datasets. Neither a single diet observation nor a stressed-cell experiment defines causation in human AD. Broad claims about "palm bioactives" obscure these sharply different compounds and may be clinically misleading.

Theme VI — Translation Fails when Exposure, Genotype and Function are Disconnected

The literature reveals a substantial asymmetry: mechanistic APOE4 glial studies are increasingly sophisticated, whereas palm-constituent studies generally do not employ the specific genotype-controlled lipid endpoints needed to establish intersection. Strong causal evidence for a disease mechanism and plausible generic activity of a compound are two separate premises; their conjunction is not proof of treatment efficacy. The weakest common links are verified cerebral exposure, isoform-resolved testing, lipidomic confirmation, longitudinal glia–neuron rescue, and robust human endpoints. At present the research opportunity is to close those links experimentally, not to advertise a finished intervention. This is an important finding because it redirects resources from broad supplement claims toward well-powered, mechanistically discriminating comparisons.

Discussion and Analysis

Integrating the Themes: An APOE-Stratified Lipid-Competence Model

A synthesis of the six themes supports an explanatory model in which APOE genotype influences lipoprotein cargo, receptor engagement, endosomal–lysosomal processing, and the cellular balance between lipid storage and utilisation. Disease-associated challenges modify this balance, potentially creating droplets that are initially protective yet become associated with inflammatory or neurotoxic states when turnover and compartmental transport fail. A candidate intervention should be said to restore "lipid competence" only if it improves the cell's ability to route and use lipids while preserving critical membrane and phagocytic functions. It is insufficient to demonstrate lower fluorescence from a lipid-droplet dye or a smaller inflammatory transcriptional signature. Genetic effects, time-course observations, and neuron-containing functional assays must converge on a biologically coherent rescue.

The model also requires distinguishing APOE lipidation from APOE genotype. The presence of an ε4 allele does not specify how fully a secreted lipoprotein particle is lipidated or what cargo it carries under a given condition. Lipidation-dependent interactions can alter immunometabolism and lysosomal routing independently of simple allele counts. Therefore, a three-genotype comparison should include measurement of ApoE abundance, particle lipidation, receptor-mediated uptake, sterol trafficking, and downstream organelle stress. This approach allows an intervention to reveal whether it operates directly on APOE-linked transport, indirectly on oxidative injury, or through an unrelated cytoprotective mechanism. Each result has different therapeutic meaning.

A Conditional, Not Indiscriminate, Strategy for Lipid Droplets

A therapeutic programme that aims merely to reduce lipid droplets is attractive because its apparent success can be documented rapidly using imaging. It is also scientifically dangerous. Under active phagocytosis, triglyceride synthesis may limit exposure to non-esterified fatty acids, while excessive retention may burden lysosomes or retain oxidised species. The correct intervention point could thus be synthesis, selective turnover, fatty-acid desaturation, lysosomal recovery, or intercellular transfer, depending on the rate-limiting lesion. Experimental factorial designs should compare early and late treatment, short and prolonged Aβ challenge, and resting versus phagocytic conditions, with direct measurement of oxidation and cell viability. Contradictory outcomes should be interpreted as possible state dependence rather than automatically dismissed as experimental noise.

The proposed readout panel includes droplet number and diameter; mass-spectrometry-resolved neutral lipid species; oxidised phospholipids; lysosomal pH and enzymatic competence; autophagic flux; cholesterol localisation; mitochondrial respiration; microglial debris uptake; astrocytic substrate transfer; and neuronal electrophysiology or survival. Imaging should use orthogonal techniques and, where feasible, stable-isotope pulse–chase tracing to reveal whether lipid pools are moving instead of merely changing volume. Prolonged follow-up is particularly important because a compound may shift an early protective store into a later harmful release of unesterified lipids. This design implements the general principles of lipid-droplet organelle biology and avoids simplistic biomarker substitution.

Compound-Specific Translational Ranking

Tocotrienols currently occupy a relatively strong hypothesis-generating position for oxidative membrane damage and possibly selected inflammatory pathways, but not for demonstrated APOE4 lipid-droplet correction. Their priority should be conditional on a dose–exposure map, separate α/γ/δ isomer experiments, stable formulations, and evidence that a protective effect persists after controlling for nonspecific antioxidant activity. Where ferroptosis is proposed, investigators should meet robust criteria such as rescue by established pathway controls, measurements of lipid peroxidation, and distinction from apoptosis or other forms of injury. Subsequent experiments should test whether improved membrane integrity is accompanied by corrected glial lipid handling and preserved neuronal function, rather than stopping at decreased oxidative markers.

Phytosterols should enter a separate sterol-traffic pathway. Beta-sitosterol, stigmasterol, and campesterol, for instance, ought not to be collapsed into a single exposure, particularly when central access and systemic metabolism may differ. Prioritisation requires resolving whether observed associations reflect transport into cerebrospinal fluid, changes in circulating cholesterol profiles, indirect gut–brain effects, or interaction with APOE-related receptor pathways. APOE-stratified sterol exposure must establish that correcting one compartment does not produce excess accumulation in another. Existing genetic-inference, longitudinal,

and laboratory studies justify that question but do not settle the safety or clinical benefit of increasing brain phytosterol exposure.

Squalene is best assigned exploratory status until reproducible CNS pharmacokinetics and APOE-isogenic glial data become available. Its biological placement upstream of sterol synthesis raises a specific safety concern: changing precursor availability might influence cholesterol homeostasis without correcting the impaired transport responsible for APOE4-associated dysfunction. By comparison, palmitate-rich fractions should not be nominated for therapeutic escalation merely because they originate in the same plant as tocotrienols. Their evaluation must consider physiologic necessity, chain-specific and dose-specific effects, lipotoxic challenge thresholds, and possible systemic metabolic consequences. These distinctions make chemical fractionation and analytical documentation prerequisites for mechanistic reproducibility.

Table 1 consolidates the candidate-specific appraisal into a practical evidence matrix. It deliberately separates mechanistic plausibility from demonstrated disease-specific target engagement, and its priorities refer to research testing rather than dietary or clinical recommendations. Each row specifies an experimental result that could strengthen or refute a compound–pathway proposition, with interpretation conditional on brain exposure and APOE genotype.

Table 1: Evidence-Calibrated Appraisal of Palm-Derived Constituent Classes and Decisive Experimental Requirements

Candidate class	Current Rationale and Evidence Boundary	Minimum Genotype-Sensitive Validation
Tocotrienols (α/γ/δ)	Adjacent evidence for lipid-peroxidation or inflammatory signalling; no established APOE4-specific glial rescue.	Isomer-resolved CNS exposure; APOE2/3/4 glial lipidomics and oxidative-injury assays; replicated neuronal rescue.
Phytosterols	Sterol transport and inflammatory pathways are plausible; central effects and clinical direction remain uncertain.	Sterol-species brain disposition; compartmental cholesterol traffic; functional comparison across APOE genotypes.
Squalene	Cell-based stress-response observations are exploratory and not evidence of restored glial lipid competence.	Quantified brain exposure; distinguish sterol synthesis effects from correction of lysosomal or ApoE trafficking.
Palmitate-rich fractions	Physiological substrate with dose- and context-dependent lipotoxic potential; not a uniform neuroprotective class.	Dose–response and species-resolved lipid profiling; assess inflammation, mitochondrial stress and cell survival.

Table 1 makes the research ranking explicit: the strongest current compound-level rationale concerns tocotrienol-related oxidative lipid endpoints, whereas phytosterols and squalene require substantially more central exposure and trafficking data. These categories are not efficacy grades, since none has demonstrated APOE4-stratified clinical benefit in Alzheimer's disease. A future study should progress only when chemical identity, exposure, lipid-processing recovery and functional benefit align in a repeatable experimental model.

Experimental Architecture: From Isogenic Glia to Systems-Level Outcomes

We propose a first experimental tier using human iPSC-derived astrocytes and microglia from APOE2/2, APOE3/3, and APOE4/4 backgrounds, preferably generated using isogenic editing and replicated across independent donor lines. Cells should be characterised for maturity, lipidation status, and baseline lipid biology before exposure. Both Aβ-related and non-Aβ stressors can be used, but investigators must avoid interpreting the former as a complete recreation of AD. Candidate compounds should be analytically verified, supplied across non-cytotoxic concentration ranges, and tested at matched intracellular exposures. Vehicle, reference-compound, genetic-rescue, and relevant pathway-inhibition controls allow target attribution; parallel assays determine whether any response is genotype-specific or general cytoprotection.

The second tier should add glia–neuron and glia–oligodendrocyte co-cultures, ideally with genetically matched combinations and selective treatment of different cell compartments. Neuronal survival, synaptic activity, amyloid processing, tau pathology, and myelination represent distinct functional tests, not automatically interchangeable markers of AD reversal. Organotypic or multicellular systems should identify whether improved astrocytic lipid management shifts cargo into a harmful microglial state, or whether microglial uptake protects neurons while stressing oligodendrocytes. Longitudinal single-cell transcriptomics, targeted proteomics, spatial lipidomics, and pulse–chase tracing can support causal inference when anchored to an intervention and predefined functional predictions.

Functional endpoints should reflect direct evidence that altered microglial lipid handling can change neuronal network behaviour, not only cell viability. Victor et al. (2022) used human stem-cell-derived systems to connect APOE4-associated microglial lipid accumulation with diminished surveillance of neuronal activity, identifying network-level measures as a meaningful translational intermediate. Accordingly, electrophysiological or calcium-imaging outcomes should be coupled with controlled microglial uptake, lipidomic profiling and genotype comparisons to distinguish restored communication from generic cytoprotection.

In a third tier, disease-appropriate animal models and, if justified, early human experimental medicine studies should connect measured brain exposure with genotype-dependent target engagement. Pharmacokinetics must distinguish total plasma drug, bioavailable form, tissue distribution, and active intracellular concentration; metabolic transformation of tocotrienol isomers or sterols may change the relevant agent. Human endpoints should be stage-specific and consistent with biomarker-based AD definitions, while avoiding premature adoption of cognition as the sole outcome of a small target-engagement trial. Explicit stop criteria include inadequate brain exposure, consistent cellular injury, beneficial effects limited to irrelevant dose ranges, or failure to replicate APOE-dependent functional rescue (Jack et al., 2024; Sharif et al., 2023; Chabriat et al., 2026).

Figure 3 translates the preceding synthesis into five sequential evidence gates for genotype-sensitive compound appraisal.

Investigators should establish chemical identity and credible central nervous system (CNS) exposure before seeking APOE-stratified molecular effects and downstream rescue of glial and neuronal function. A green go decision requires replicated, functionally relevant benefit at non-toxic exposure, whereas isolated droplet reduction, toxicity or lack of genotype-sensitive functional evidence triggers a stop or redesign decision.




Figure 3: Proposed Genotype-Stratified Sequence for Bioactive Intervention Appraisal

Figure 3 formalises the five appraisal gates, from verified compound identity and exposure through genotype-resolved mechanism and functional co-culture rescue. Its bifurcated decision rule keeps apparent molecular activity separate from evidence sufficient to justify continued therapeutic development. Especially for plant-derived formulations, these stop criteria discourage advancement based solely on appealing lipid-droplet images, high but implausible laboratory concentrations, or general antioxidant endpoints.

Evidence-Discrimination Matrix and Falsifiable Predictions

Three grades of claim should be kept visibly distinct in reports. Grade A is directly observed genotype-linked glial or brain biology, exemplified by APOE4-dependent lipid phenotypes; Grade B is mechanistic correspondence established in a different cell system or disease; and Grade C is a plausible but untested link between a palm-derived compound and APOE4-dependent AD outcomes. These labels are qualitative signposts, not a claim that a formal risk-of-bias instrument was used. For example, "APOE4 modifies glial droplets" may be directly supported, "tocotrienols reduce some forms of lipid oxidative stress" may be supported in adjacent models, while "tocotrienols rescue APOE4-driven cognitive decline" is currently unproven. Making the chain explicit protects against a common inferential error in cross-disciplinary reviews.

Several predictions are falsifiable. If tocotrienols primarily protect membranes from peroxidation, oxidised phospholipid species and injury markers should improve even where droplet number remains unchanged; if they instead normalise lipid trafficking, lysosomal sterol distribution and flux must recover. If a specific phytosterol acts on APOE-dependent transport, an APOE4-selective difference in lipoprotein uptake or sterol movement should persist after matching systemic exposure. If squalene acts chiefly on the stress response, its effects may fail to correct ApoE lipidation and neuron–glia cargo exchange. If droplet depletion is harmful during acute phagocytic stress, protective cell functions should deteriorate despite an apparently favourable imaging readout. Competing outcomes of this type would sharply distinguish therapy-relevant mechanisms.

Disease Heterogeneity, Equity and Precaution in Human Translation

A genotype-centred model should not become genotype reductionism. APOE alleles interact with age, sex, vascular risk, metabolic state, ancestry, and environmental exposure, while disease progression involves more than lipid biology. One potential hazard is overgeneralising findings from cell lines derived from a narrow genetic background or a single tissue source. Another is relying on commercial formulations with variable chemical profiles and assuming that a generic botanical label denotes an equivalent intervention. Research programmes should predefine chemical specifications, report donor background, include both sexes where feasible, and seek external replication before suggesting subgroup benefit. Public-facing claims should remain proportional to the evidence, particularly where consumer supplements may be interpreted as alternatives to evidence-based AD care.

Environmental and supply-chain considerations matter for palm-derived inputs, but they are not evidence of neurological efficacy. Sustainable extraction, reliable quality control, fraction purity, contaminant limits, and traceable raw materials would be prerequisites for any eventual clinical product; they cannot compensate for absent mechanistic or safety data. Equally, a negative result for one fraction or formulation should not be generalised across all palm-derived molecules. The responsible development pathway links upstream sourcing to reproducible chemistry, quantitative exposure, cell-state-specific efficacy, and clinically relevant benefit, with safety and patient welfare taking precedence over the appeal of natural-product narratives.

This separation of product provenance from biological proof strengthens both scientific integrity and potential downstream innovation.

Implications for Theory and Research Governance

The proposed framework changes what counts as a successful experiment. Instead of maximising generic antioxidant readouts or minimising droplets, it asks whether a chemically defined molecule restores the coordination of lipid uptake, buffering, redistribution, degradation, and utilisation in genetically defined glia. This shifts attention from molecular associations toward an intervention-sensitive theory of lipid processing competence. It also reconciles apparently opposite findings on triglyceride metabolism: storage formation may be adaptive in the short term, whereas persistence under defective turnover may contribute to damage. A time-resolved, cell-resolved theory can accommodate both observations without declaring one a universal exception.

Research governance should reward reproducibility of mechanism and transparent negative results. Pre-registration of key endpoints is useful for confirmatory experiments even though this QLR itself is not a registered systematic review. Shared protocols for lipidomics, lipid-droplet imaging, ferroptosis criteria, and APOE isogenic controls would reduce the likelihood that differences in dye thresholds or dose formulation appear to be biological disagreement. Studies should state when effects are restricted to a particular isomer, treatment window, stressor, sex, genotype, or platform. A staged go/no-go pathway is more valuable than accumulating mechanistic cartoons that fail to specify falsification conditions or clinically plausible dose ranges [1-57].

Conclusion and Comprehensive Recommendations

The emerging literature supports APOE-sensitive dysfunction of brain lipid trafficking, lysosomal processing, and glial lipid-droplet regulation as a substantive dimension of Alzheimer's disease biology. It does not establish that reducing lipid-droplet abundance is universally therapeutic, nor that palm-derived compounds have already corrected these abnormalities in patients. The principal conclusion is mechanistic and conditional: adaptive storage, persistent storage, lipid oxidation, and intercellular transfer must be distinguished before intervention targets are chosen. Cell type, disease context, genotype, lipid species, and timing determine whether a given lipid-handling response is likely to support resilience or contribute to injury.

Tocotrienols merit the most immediate compound-specific investigation for oxidative-lipid and selected signalling endpoints, subject to verified CNS exposure and rigorous APOE-isogenic testing. Phytosterols require careful sterol-species and compartment-specific investigation, given the difference between peripheral lipid effects and brain sterol handling. Squalene remains exploratory and should not be promoted beyond its current mechanistic evidence, while saturated fatty-acid fractions demand dose-sensitive toxicological evaluation and should not be described as a uniformly neuroprotective category. These positions are research priorities, not clinical treatment recommendations.

A comprehensive programme should combine isogenic human glial comparisons, longitudinal lipid flux measurement, lysosomal and mitochondrial phenotyping, neuronal functional co-culture outcomes, and exposure-linked animal studies before human efficacy claims are entertained. It should include positive and negative mechanistic controls, test both acute and chronic stress states, compare APOE2/3/4, and reject interventions whose apparent success is confined to droplet reduction without functional recovery. The overarching contribution is an evidence-calibrated, genotype-sensitive approach that transforms the broad question of whether natural palm constituents are neuroprotective into precise, refutable questions about the restoration of lipid-processing competence in Alzheimer's disease.

References

1. Adeniyi PA (2023) Ferroptosis of microglia in aging human white matter injury. Annals of Neurology 94: 1048–1066.
2. Bellenguez C (2022) New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics 54: 412–436.
3. Blanchard JW (2022) APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature 611: 769–779.
4. Chabriat H (2026) Tocotrienol-rich vitamin E complex in CADASIL (T3CAD): a randomised, double-blind, placebo-controlled trial. eClinicalMedicine 94: 103853.
5. Chmielarz M (2023) Palmitic acid modulates microglial cell response to metabolic endotoxemia in an in vitro study. Nutrients 15: 3463.
6. Clark C (2023) Plant sterols and cholesterol metabolism are associated with five-year cognitive decline in the elderly population. iScience 26: 106740.
7. Cuní-López C (2026) APOE genotypes differentially remodel the astrocytic lipid droplet proteome to shape lipid droplet dynamics. Nature Communications 17: 9900.
8. Dixon SJ, Olzmann JA (2024) The cell biology of ferroptosis. Nature Reviews Molecular Cell Biology 25: 424–442.
9. Fan L (2023) Associations of circulating saturated long-chain fatty acids with risk of mild cognitive impairment and Alzheimer's disease in the ADNI cohort. eBioMedicine 97: 104818.
10. Farese RV, Walther TC (2025) Essential biology of lipid droplets. Annual Review of Biochemistry 94: 447–477.
11. Fitz NF (2021) Phospholipids of APOE lipoproteins activate microglia in an isoform-specific manner in preclinical models of Alzheimer's disease. Nature Communications 12: 3416.
12. Fu JY (2023) Effect of nano-delivery systems on the bioavailability and tissue biodistribution of vitamin E tocotrienols. Food Research International 171: 113048.
13. Ganamurali N, Varsha SB, Sabarathinam S (2025) Phytosterols as modulators of gut–brain axis and neuroinflammation in Alzheimer's disease: a novel therapeutic avenue in aging research. Journal of Steroid Biochemistry and Molecular Biology 254: 106836.
14. Guo X (2024) Deciphering the effect of phytosterols on Alzheimer's disease and Parkinson's disease: the mediating role of lipid profiles. Alzheimer's Research & Therapy 16: 53.
15. Guo JL (2025) Decreased lipidated ApoE–receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell 188: 187–206.e26.
16. Haney MS (2024) APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia. Nature 628: 154–161.
17. Heneka MT (2025) Neuroinflammation in Alzheimer disease. Nature Reviews Immunology 25: 321–352.
18. Henne WM, Cohen S (2026) Heterogeneity, dynamics and organelle interactions of lipid droplets. Nature Reviews Molecular Cell Biology 27: 433–449.
19. Ismail M (2020) Safety and neuroprotective efficacy of palm oil and tocotrienol-rich fraction from palm oil: a systematic review. Nutrients 12: 521.
20. Jack CR (2024) Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.

Alzheimer's & Dementia 20: 5143–5169.
21. Jackson RJ, Hyman BT, Serrano-Pozo A (2024) Multifaceted roles of APOE in Alzheimer disease. Nature Reviews Neurology 20: 457–474.
22. Jahn T (2021) Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression. Journal of Steroid Biochemistry and Molecular Biology 205: 105785.
23. Jie F (2022) Stigmasterol attenuates inflammatory response of microglia via NF-κB and NLRP3 signaling by AMPK activation. Biomedicine & Pharmacotherapy 153: 113317.
24. Kim WS, Halliday GM (2026) Astrocytic lipid dysregulation as an early driver of neurodegeneration. Nature Reviews Neurology 22: 485–497.
25. Kozlova A (2025) PICALM Alzheimer's risk allele causes aberrant lipid droplets in microglia. Nature 646: 1178–1186.
26. Lee SI (2021) APOE4-carrying human astrocytes oversupply cholesterol to promote neuronal lipid raft expansion and Aβ generation. Stem Cell Reports 16: 2128–2137.
27. Lee HG, Wheeler MA, Quintana FJ (2022) Function and therapeutic value of astrocytes in neurological diseases. Nature Reviews Drug Discovery 21: 339–358.
28. Lee H (2023) ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes. Cell Reports 42: 113183.
29. Liu CC (2023) Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease. Nature Immunology 24: 1854–1866.
30. Liu Y, Chen Y, Fukui K (2024) α-Tocotrienol protects neurons by preventing tau hyperphosphorylation via inhibiting microtubule affinity-regulating kinase activation. International Journal of Molecular Sciences 25: 8428.
31. Mao M (2025) Microglial APOE4 promotes neuron degeneration in Alzheimer's disease through inhibition of lipid droplet autophagy. Acta Pharmaceutica Sinica B 15: 657–660.
32. Marschallinger J (2020) Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nature Neuroscience 23: 194–208.
33. Mathew AM (2023) Exploring the anti-inflammatory activities, mechanism of action and prospective drug delivery systems of tocotrienol to target neurodegenerative diseases. F1000Research 12: 338.
34. Mishima E (2025) Recommendations for robust and reproducible research on ferroptosis. Nature Reviews Molecular Cell Biology 26: 615–630.
35. Nugent AA (2020) TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron 105: 837–854.e9.
36. Petrelli F (2026) Cellular mechanisms of brain lipid metabolism in health and disease. Nature Cell Biology 28: 421–435.
37. Prakash P (2025) Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer's disease. Immunity 58: 1536–1552.e8.
38. Qi G (2021) ApoE4 impairs neuron–astrocyte coupling of fatty acid metabolism. Cell Reports 34: 108572.
39. Rachmian N (2024) Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain. Nature Neuroscience 27: 1116–1124.
40. Rappoport A (2025) A lipid-raft theory of Alzheimer's disease. Annual Review of Biochemistry 94: 387–416.
41. Reinicke M (2021) Plant sterol-poor diet is associated with pro-inflammatory lipid mediators in the murine brain. International Journal of Molecular Sciences 22: 13207.
42. Sarikamis Johnson B (2025) Exploring the effects of squalene in the PERK/ATF4/eIF2α/CHOP signalling pathway in an in vitro Alzheimer disease model and in silico approach. Metabolic Brain Disease 40: 300.
43. Sharif M (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review. Journal of the Pakistan Medical Association 73: 603–610.
44. Shiferaw TG (2026) ApoE lipidation state directs immunometabolic reprogramming of human microglia. Alzheimer's & Dementia 22: e71882.
45. Smith ME, Bazinet RP (2024) Unraveling brain palmitic acid: origin, levels and metabolic fate. Progress in Lipid Research 96: 101300.
46. Spinedi M (2024) Cholesterol-metabolism, plant sterols, and long-term cognitive decline in older people: effects of sex and APOEe4. iScience 27: 109013.
47. Stephenson RA (2025) Triglyceride metabolism controls inflammation and microglial phenotypes associated with APOE4. Cell Reports 44: 115961.
48. Sung S (2026) Microglial lipid droplets as therapeutic targets in age-related neurodegenerative diseases. npj Aging 12: 2.
49. Tcw J (2022) Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell 185: 2213–2233.e25.
50. Thorwald MA (2025) Iron-associated lipid peroxidation in Alzheimer's disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice. Alzheimer's & Dementia 21: e14541.
51. van Lengerich B (2023) A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models. Nature Neuroscience 26: 416–429.
52. Vanherle S (2025) Lipid metabolism, remodelling and intercellular transfer in the CNS. Nature Reviews Neuroscience 26: 214–231.
53. Victor MB (2022) Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. Cell Stem Cell 29: 1197–1212.e8.
54. Windham IA (2024) APOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size. Journal of Cell Biology 223: e202305003.
55. Xu Z (2025) Microglia-specific regulation of lipid metabolism in Alzheimer's disease revealed by microglial depletion in 5xFAD mice. Nature Communications 16: 9156.
56. Yang H (2026) Tocotrienols exhibit superior ferroptosis inhibition over tocopherols. Scientific Reports 16: 4497.
57. Zhang L (2025) Lipid droplets in central nervous system and functional profiles of brain cells containing lipid droplets in various diseases. Journal of Neuroinflammation 22: 7.

Copyright: ©2026 Loso Judijanto. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.